Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|10|2|142-145

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.10, Iss.2, 2015-01, pp. : 142-145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Near-Complete Response to Treatment with Gemcitabine plus nab®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-10 ,pp. : 711-717

Karger

Access to resources Recommend Favorite

Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine

By  

Oncology Research and Treatment, Vol. 38, Iss. 11, 2015-0 ,pp. : 596-603

Karger

Access to resources Recommend Favorite

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 648-655

Karger

Access to resources Recommend Favorite

Is Gemcitabine plus Vinorelbine Active in Second-Line Chemotherapy of Metastatic Breast Cancer? A Single-Center Phase 2 Study

By  

Oncology, Vol. 64, Iss. 4, 2003-05 ,pp. : 479-480

Karger

Access to resources Recommend Favorite

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-06 ,pp. : 571-576

Karger

Access to resources Recommend Favorite